首頁 > 市場調查報告書 > 醫療設備

生技設備

市場調查報告書

商品編碼

1624395

2024 年至 2031 年原位雜化市場（按技術、應用、最終用戶和地區劃分）

In Situ Hybridization Market By Technique (Fluorescent In Situ Hybridization, Chromogenic In Situ Hybridization, Radioactive In Situ Hybridization ), Application, End-User, & Region for 2024-2031

出版日期: 2024年08月23日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

原位雜交市場評估，2024-2031

由於原位雜交 (ISH) 在包括癌症在內的多種疾病的檢測和研究中具有重要意義，因此對其的需求日益增長。 ISH 是一種先進的技術，可以幫助科學家和醫療專業人員識別組織切片內的特定核酸序列。該技術對於檢測基因異常、傳染性病原體以及天然組織中特定基因的表達至關重要。隨著癌症和其他遺傳疾病的發生率上升，對ISH 等精確可靠的診斷方法的需求將不斷增長，推動市場收入在2024 年超過18.1 億美元，到2031 年達到18.1 億美元。估值至約 33.8 億美元。

將 ISH 與其他現代診斷技術（如免疫組織化學和下一代定序）結合，可以更全面地瞭解疾病的病理生理學。這種綜合方法在個人化醫療中特別有用，因為廣泛的分子分析對於根據個別患者制定治療方案至關重要。因此，ISH 研究在臨床診斷、轉化研究和藥物發現中日益廣泛的應用，正在推動醫療保健和生物技術行業的需求，預計 2024 年至 2031 年期間的複合年增長率為 8.97%。

原位雜交市場定義/概述

原位雜交 (ISH) 是一種有效的科學技術，用於檢測組織片段或細胞等樣本內的 DNA 或 RNA 特定序列。 "In Situ" 一詞的意思是 "原位" ，這種技術使科學家能夠精確定位這些遺傳元素在其生物環境中的具體位置。以RNA 的形式）在何處）位於組織細胞中，為瞭解基因表現模式和細胞功能提供了重要依據。

原位雜交經常用於研究和醫學診斷，因為它可以提供空間和分子資訊。其主要應用之一是在發育生物學領域，有助於瞭解基因在生物體生長發育過程中如何受到調控和表現。

ISH 的未來應用有望為包括醫學診斷和研究在內的各個領域帶來變革性的變化。最有趣的未來應用之一是個人化醫療。隨著醫療保健領域轉向更個人化的治療策略，ISH 在發現與包括癌症在內的各種疾病相關的特定遺傳標記方面可以發揮重要作用。

遺傳疾病和癌症發生率的不斷上升會推動原位雜交市場的發展嗎？

遺傳疾病和癌症發生率的不斷上升是原位雜交 (ISH) 業務的主要推動力。根據世界衛生組織（WHO）的數據，癌症是全球第二大死因，到2020年將有約1,000萬人死於癌症。全球癌症發生率的不斷上升使得人們必須使用 ISH 等現代診斷技術來可靠地檢測和表徵腫瘤。美國國家癌症研究所估計，39.5% 的男性和女性在一生中的某個階段會被診斷出罹患癌症。這種較高的終生風險凸顯了對 ISH 等精準診斷技術日益增長的需求。

對個人化治療和標靶藥物的日益重視也促進了 ISH 市場的擴張。據美國國立衛生研究院（NIH）稱，基因醫學的發展已經促成了300多種針對包括癌症在內的各種疾病的定製藥物的開發。 ISH 技術對於尋找遺傳標記和生物標記以預測治療決策和患者結果至關重要。此外，老年人口不斷增長，更容易患上遺傳疾病和癌症，這也推動了對 ISH 技術的需求。聯合國預測，到 2050 年，全球每六人中就有一人年齡超過 65 歲，而 2019 年這一數字為每 11 人中就有一人。

熟練專業人員的短缺會阻礙原位雜交市場的發展嗎？

合格專業人員的短缺可能會影響原位雜交 (ISH) 市場。然而，一些因素似乎有助於消除這種擔憂。首先，對精準醫療和個人化醫療保健的日益重視推動了對 ISH 等分子診斷工具的需求。據美國國立衛生研究院稱，精準醫療計畫在全國招募超過 100 萬名志願者進行研究，以強調個人化治療的必要性。這一趨勢必將鼓勵更多的專業人士專注於相關職業。此外，ISH 技術的進步（例如自動化儀器和簡化協議的創建）使得更廣泛的實驗室人員能夠使用這種方法。

此外，教育機構和行業協會正在積極努力縮小技能差距。美國臨床病理學會 (ASCP) 報告稱，2013 年至 2018 年間，完成認證計畫的實驗室專業人員數量增加了 7.1%。此外，美國勞工統計局預測，2019 年至 2029 年間，醫學實驗室技術人員和臨床實驗室科學家技術人員的就業機會將增加 7%，高於整體平均水準。這種增長表明專門從事 ISH 程序的潛在專家數量正在增加。此外，交叉培訓計劃和繼續教育機會變得越來越普遍，使現有實驗室員工能夠拓寬他們的技能。

The growing need for In Situ Hybridization (ISH) is motivated by its importance in detecting and researching numerous diseases including cancer. ISH is a sophisticated technology that enables scientists and medical practitioners to identify specific nucleic acid sequences within tissue slices. This skill is critical for detecting genetic anomalies, infectious agents, and the expression of certain genes in their natural tissue context. As the incidence of cancer and other genetic illnesses rises, the necessity for precise and dependable diagnostic methods like ISH grows by enabling the market to surpass a revenue of USD 1.81 Billion valued in 2024 and reach a valuation of around USD 3.38 Billion by 2031.

The combination of ISH and other modern diagnostic techniques such as immunohistochemistry and next-generation sequencing is yielding more comprehensive insights into disease pathophysiology. This comprehensive method is especially useful in personalized medicine where extensive molecular profiling is essential for personalizing treatments to individual patients. As a result, ISH's rising applications in clinical diagnostics, translational research, and drug discovery are driving up demand in the healthcare and biotechnology industries by enabling the market to grow at aCAGR of 8.97% from 2024 to 2031.

In Situ Hybridization Market: Definition/ Overview

In situ hybridization (ISH) is an effective scientific technique for detecting specific sequences of DNA or RNA within a sample such as a tissue segment or a cell. The phrase "in situ" means "in place," implying that this technology enables scientists to pinpoint the specific location of these genetic elements inside the biological milieu. Essentially, ISH allows researchers to see where certain genes or their activity (in the form of RNA) are situated in a tissue's cells providing vital insights into gene expression patterns and cellular function.

In situ hybridization is frequently utilized in research and medical diagnostics because of its ability to offer both spatial and molecular information. One of its key applications is in the field of developmental biology where it assists scientists in understanding how genes are regulated and expressed throughout organismal growth and development.

The future application of ISH is expected to transform a variety of disciplines including medical diagnostics and research. One of the most intriguing future uses is personalized medicine. As the healthcare sector shifts toward more personalized treatment strategies, ISH can play an important role in discovering specific genetic markers linked to various diseases including cancer.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Will the Rising Incidence of Genetic Disorders and Cancer Drive the In Situ Hybridization Market?

The increasing incidence of genetic diseases and cancer is a major driver of the in situ hybridization (ISH) business. According to the World Health Organization (WHO), cancer is the world's second biggest cause of death accounting for roughly 10 million deaths by 2020. The rising global cancer incidence needs the use of modern diagnostic techniques such as ISH for reliable tumor detection and characterization. The National Cancer Institute estimates that 39.5% of men and women will be diagnosed with cancer at some point in their lives. This high lifetime risk highlights the increasing need for precise diagnostic techniques like ISH.

The growing emphasis on individualized treatment and targeted medicines also helps to expand the ISH market. The National Institutes of Health (NIH) says that developments in genetic medicine have resulted in the development of over 300 tailored drugs for a variety of disorders including cancer. ISH techniques are critical for finding genetic markers and biomarkers that inform therapy decisions and predict patient outcomes. Furthermore, the expanding older population which is more vulnerable to genetic illnesses and cancer increases the demand for ISH technology. The United Nations projects that by 2050, one in every six persons worldwide will be beyond the age of 65, up from one in every eleven in 2019.

Will Shortage of Skilled Professionals Hamper the In Situ Hybridization Market?

A shortage of competent specialists could influence the in situ hybridization (ISH) market; however, numerous factors may help to offset this concern. First, the growing emphasis on precision medicine and individualized healthcare is increasing demand for molecular diagnostic tools such as ISH. According to the National Institutes of Health, the Precision Medicine Initiative intends to enroll 1 million or more volunteers in a national study cohort emphasizing the need for personalized treatment procedures. This tendency will certainly encourage more professionals to specialize in related professions. Furthermore, advances in ISH technology such as the creation of automated equipment and streamlined protocols are making the approach more accessible to a wider spectrum of laboratory personnel.

Additionally, educational institutions and industry associations are actively attempting to close the skills gap. The American Society for Clinical Pathology (ASCP) reported a 7.1% rise in the number of laboratory professionals who completed certification programs between 2013 and 2018. Furthermore, the U.S. Bureau of Labor Statistics predicts that medical and clinical laboratory technologist and technician jobs will expand by 7% between 2019 and 2029 faster than the overall average. This increase indicates an expanding pool of potential specialists who could specialize in ISH procedures. Furthermore, cross-training programs and continuing education opportunities are becoming more common allowing current laboratory employees to broaden their skill sets.

Category-Wise Acumens

Will the Development of Advanced Fluorescent Dyes and Imaging Technologies Influence the Technique Segment?

Fluorescent chromogenic in situ hybridization (CISH) is also an important technique, however it is less prevalent than FISH. CISH employs chromogenic substrates to provide a visible color reaction that is persistent and easy to interpret using a conventional light microscope. This method is especially useful in pathology laboratories for tissue-based analysis where persistent staining is required for long-term storage and examination of samples. While CISH has advantages in terms of visibility and ease of use, it does not match FISH's multiplexing capability and sensitivity.

In Situ, Hybridization (FISH) is currently the most common technique. FISH's extensive adoption and supremacy can be due to its great sensitivity, adaptability, and ability to perform multiplexing. This technology uses fluorescently labeled probes that bind to specific nucleic acid sequences within cells or tissues allowing researchers and physicians to observe and evaluate several targets at the same time using sophisticated fluorescence microscopy. FISH is especially useful in cytogenetics, where it is used to detect chromosomal abnormalities, and in cancer research to find genetic alterations and gene amplifications. Its ability to produce precise and consistent results makes it a popular choice in both clinical diagnosis and research contexts.

Will the Increasing Demand for Oncological Research and Clinical Practice Drive Growth in the Application Segment?

The demand for in situ hybridization for cancer diagnosis and research is one of the primary applications. This dominance stems from ISH's crucial role in detecting and defining specific genetic changes linked to distinct malignancies. Cancer research and diagnosis greatly benefit from ISH's capacity to detect gene amplifications, translocations, and biomarker expression levels in tissue samples. For example, ISH techniques are critical for identifying malignancies such as breast cancer as they can detect HER2 gene amplifications and guide therapy options. The rising global prevalence of cancer combined with a growing emphasis on individualized care fuels the demand for precise and dependable diagnostic techniques such as ISH. Furthermore, advances in ISH technology have improved its potential to deliver deep molecular insights which are critical for creating targeted medicines and improving patient outcomes.

Neuroscience is another important application, however not as prevalent as cancer diagnosis. ISH is used in neuroscience to analyze gene expression patterns in the brain and nervous system which is critical for understanding neurological illnesses and brain development. Researchers utilize ISH to map gene expression in different brain regions revealing information about illnesses including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. The detailed spatial resolution of ISH enables scientists to explore how specific genes influence brain function and pathology, hence contributing to the creation of new treatments. While neurology is a rising and essential sector for ISH applications, cancer diagnosis remains the principal market driver owing to the urgent and high-impact clinical demand for precise and actionable cancer-related genetic information.

Country/Region-wise Acumens

Will Technologically Upgraded Infrastructure Drive the Growth in the North American Region?

The in situ hybridization (ISH) market in North America is expected to grow significantly owing mostly to technical advancements in infrastructure. The region's rising cancer prevalence is a significant driver. The American Cancer Society estimates that in 2023, there will be 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States alone. Given the high incidence rate, improved diagnostic approaches such as ISH are required for reliable detection and treatment planning. Furthermore, the expanding use of personalized medicine approaches is increasing the demand for ISH procedures. According to the National Institutes of Health, precision medicine programs have garnered more than USD 200 Million in funding since 2015, demonstrating the value of personalized therapy tactics.

Another key contributor is North America's strong research and development infrastructure. The United States leads the world in biomedical research funding with the National Institutes of Health budget reaching USD 45 Billion by 2021. This significant investment encourages advancements in ISH technologies and applications. Furthermore, the presence of large pharmaceutical and biotechnology companies in the region helps to drive market expansion. According to the Pharmaceutical Research and Manufacturers of America (PhRMA), the US biopharmaceutical sector will invest an estimated USD 102.3 Billion in R&D in 2021, with a large amount of that going toward developing and implementing advanced diagnostic technologies such as ISH. The region's supremacy in the ISH market is also due to its well-developed healthcare infrastructure and high healthcare spending.

Will the Investments by Manufacturers & Government Boost the Market in the Asia Pacific Region?

The Asia Pacific region is poised for significant growth in the in situ hybridization (ISH) market. According to the World Health Organization, new cancer cases in Asia are expected to increase from 8.8 million in 2018 to 11.5 million by 2025. This dangerous trend has spurred manufacturers and governments to make significant investments in advanced diagnostic technologies such as ISH. For example, the Japanese government has set aside approximately 46 billion yen (approximately USD 415 Million) on cancer research and development in its 2021 budget.

Another important driver is the rapid expansion of healthcare infrastructure and rising healthcare spending in emerging economies. The Indian government, for example, has stated plans to expand healthcare spending to 2.5% of GDP by 2025, up from 1.5% today. This increase in spending is anticipated to drive up the use of advanced diagnostic procedures such as ISH. Additionally, the increased emphasis on customized medicine and tailored therapies is driving up demand for ISH approaches. According to a report by the Asia Pacific Personalized Medicine Coalition, the region's personalized medicine market is predicted to develop at a CAGR of 15.6% from 2021-2026.

Competitive Landscape

The in situ hybridization market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions, and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the in situ hybridization market include:

Thermo Fisher Scientific, Inc.

Abbott

PerkinElmer, Inc.

BioView

Agilent Technologies, Inc.

Merck KGaA

Bio-Rad Laboratories, Inc.

Latest Developments

In January 2023, Ikonisys SA teamed with Integrated Gulf Biosystems Group (IGB) to distribute the Ikoniscope20 Digital Fluorescence Microscope Solution in the Middle East, including Saudi Arabia, the UAE, Kuwait, Bahrain, and South Asian regions. This agreement intends to increase the reach of Ikonisys' oncology testing products.

In February 2023, Molecular Instruments, a spin-off of the California Institute of Technology introduced HCR RNA-CISH kits to improve automated chromogenic ISH procedures using RNAscope. These kits enable a double turnaround time at half the cost.